Inventiva 경영진

경영진 기준 점검 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Andrew Obenshain

최고경영자

€10.8m

총 보수

CEO 급여 비율	1.41%
CEO 재임 기간	less than a year
CEO 지분 보유율	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	6.1yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • May 15

Inventiva's Speculative Upside Through MASH Is Promising

Summary Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA’s balance sheet has sufficient financing to reach that readout. But please bear in mind that it’s a binary outcome. I believe that, if lanifibranor succeeds, the upside could be considerable. Conversely, if they fail, their runway would be tighter with a failed asset. On balance, IVA is the quintessential high-risk, high-reward biotech stock. But, given its promising trial data, the setup is compelling. Read the full article on Seeking Alpha

Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha

Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

CEO 보수 분석

Andrew Obenshain의 보수는 Inventiva의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Dec 31 2025	€11m	€152k	-€354m

보상 대 시장: Andrew의 총 보수(USD12.64M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.69M)보다 높습니다.

보상과 수익: Andrew의 보상을 회사 실적과 비교하기에 데이터가 부족합니다.

CEO

Andrew Obenshain (50 yo)

less than a year

재임 기간

€10,832,244

보수

Mr. Andrew Obenshain serves as Chief Executive Director at Inventiva S.A. since October 01, 2025 and served as its Director. He has been the Director of bluebird bio, Inc. since November 2021 and served as...

리더십 팀

이름	직위	재임 기간	보수	지분
Andrew Obenshain	Chief Executive Officer	less than a year	€10.83m	데이터 없음
Pierre Broqua	Co-Founder	15.3yrs	€411.80k	1.65% $ 17.1m
Jean Volatier	Executive VP Finance & Corporate Social Responsibility	less than a year	€1.47m	0.11% $ 1.2m
Martine Zimmermann	Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs	less than a year	€4.19m	데이터 없음
Jason Campagna	President of Research & Development and Chief Medical Officer	less than a year	€2.82m	데이터 없음
Axel-Sven Malkomes	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Susan Coles	Chief Legal Officer	less than a year	데이터 없음	데이터 없음
Pamela Herbster	Chief People Officer	less than a year	데이터 없음	데이터 없음
Pascaline Clerc	Executive Vice President of External and Corporate Affairs	2.6yrs	데이터 없음	0.0088% $ 91.3k
Nazira Amra	Chief Commercial Strategy Officer	no data	데이터 없음	데이터 없음

0.6yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 관리: IVA의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 0.6 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름	직위	재임 기간	보수	지분
Mark Pruzanski	Independent Chairman	1.4yrs	€14.42m	데이터 없음
Annick Schwebig	Independent Director	9.3yrs	€141.90k	0.0015% $ 15.4k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	데이터 없음
Andrew Shenker	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
Arun Sanyal	Member of Scientific Advisory Board	5.8yrs	데이터 없음	데이터 없음
Heinz Maeusli	Independent Director	7yrs	€135.60k	데이터 없음
Sven Francque	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Manal Abdelmalek	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kenneth Cusi	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Glen Clack	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gérard Zalcman	Scientific Advisory Board Member	no data	데이터 없음	데이터 없음
Elisabetta Bugianesi	Member of the Scientific Advisory Board	4.3yrs	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

70yo

평균 나이

경험이 풍부한 이사회: IVA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.1 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/31 23:39
종가	2026/05/29 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Inventiva S.A.는 23명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Eliana Merle	Barclays
Edward Nash	Canaccord Genuity
Etzer Darout	Guggenheim Securities, LLC

Inventiva 경영진

경영진 기준 점검 1/4

핵심 정보

최근 경영진 업데이트

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva S.A., Annual General Meeting, May 22, 2025

Recent updates

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva's Speculative Upside Through MASH Is Promising

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Publication in Journal of Hepatology Reports on Results of Lanifibranor Treatment on Liver Sinusoidal Endothelial Cells in Patients with MASLD/MASH and in Preclinical Models of the Disease

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor

Inventiva S.A., Annual General Meeting, May 22, 2025

Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis